— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET…
LOS ANGELES, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alchera X (AX), a global leader in AI-powered facial recognition and computer…
AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) in collaboration with the Brush and Key…
Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE…
Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 /PRNewswire/…
Hardback | Non-Fiction/Memoir | 296 pp | INR 699 Available wherever books are sold | Released 13th October 2025 NEW DELHI, Nov. 13,…
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response…
October 14, 2025 08:05 ET | Source: Candel Therapeutics NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc.…
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025, 10:30 pm CET / 4:30 pm ET –…
OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that…